INTERCEPT Blood System for Platelets, pathogen reduction system
The INTERCEPT Blood System for platelets received FDA approval in 2014, to reduce the risk of transfusion transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD).
PIPER Surveillance Study is Currently Enrolling
To extend further the safety profile of INTERCEPT platelets, Cerus is executing a post-marketing active surveillance study, or the Phase IV INTERCEPT Platelets Entering Routine use (PIPER) Study. PIPER is a prospective, open-label study designed to evaluate the transfusion of conventional and INTERCEPT treated platelets in hematology/oncology patients, including those undergoing hematopoietic stem cell transplant, who are expected to require one or more platelet component transfusions.
PIPER will evaluate of the frequency of assisted mechanical ventilation required to treat severe pulmonary complications, a common clinical concern in transfusion medicine as it relates to repeated platelet transfusions in patient populations at risk for pulmonary complications, such as hematology/oncology patients.